Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
Requires the Center for Medicare and Medicaid Innovation to test a Most-Favored-Nation (MFN) drug pricing model beginning January 1, 2029.
The model would require specified manufacturers to provide an MFN price (the second-lowest applicable net price among listed reference countries) to eligible Medicare, Medicaid, Part D, and certain provider-administered patients, and to report pricing data to the Secretary.
The pilot runs five years, allows the Secretary to suspend requirements for manufacturers likely to enter a covered agreement, and defines covered agreements that include commitments to increase U.S. manufacturing and reporting deadlines.
High controversy, strong affected-industry opposition, legal risk, and procedural hurdles make enactment uncertain despite policy salience.
Relative to its intended legislative type, this bill is a reasonably well-structured administrative mandate that directs CMMI to test a Most-Favored-Nations pricing model and supplies many necessary legal definitions and key dates. However, it relies heavily on delegated authority to the Secretary for implementation specifics, omits fiscal/resourcing discussion, and provides limited provisions for evaluation and mitigation of foreseeable operational risks.
Liberal emphasizes lowering costs and access benefits
Liberal emphasizes lowering costs and access benefits
Generally positive: views federal pilot as a concrete step to lower drug costs for public beneficiaries.
May want broader scope and stronger safeguards for access and equity; some effects are uncertain.
Cautiously supportive of a CMMI pilot to test MFN pricing if evidence, safeguards, and review mechanisms guide expansion.
Wants careful evaluation of budget, access, and innovation tradeoffs.
Likely opposed: sees the MFN pilot as government price-setting that risks innovation, supply disruptions, and federal overreach into the pharmaceutical market.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
High controversy, strong affected-industry opposition, legal risk, and procedural hurdles make enactment uncertain despite policy salience.
The bill has not accumulated any surfaced votes yet.
Liberal emphasizes lowering costs and access benefits
High controversy, strong affected-industry opposition, legal risk, and procedural hurdles make enactment uncertain despite policy salience.
Relative to its intended legislative type, this bill is a reasonably well-structured administrative mandate that directs CMMI to test a Most-Favored-Nations pricing model and supplies many necessary legal definitions an…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.